CDSCO Issues Warning After Theft of Sanofi Lantus Insulin Consignment

The Central Drugs Standard Control Organization (CDSCO) has issued a high-priority public advisory following the theft of a significant shipment of insulin pens manufactured by Sanofi India Limited. The theft occurred while the products were in transit, leading to fears that compromised medicine could enter the gray market.

Details of the Stolen Batch

The missing stock consists of Lantus SoloStar (Insulin Glargine Injection IP, r-DNA origin, 100 IU/mL). Regulatory authorities have identified the specific batch involved to help the public and healthcare providers remain vigilant:

Batch Number: 5F0347B.
Incident Location: The shipment was stolen during transport from Jagmohanpur, Odisha, to a carrying and forwarding agent in Kolkata.
Current Status: The matter is under active investigation by local police.

Critical Safety Risks: The Cold-Chain Factor

The primary concern for health officials is the stability of the medication. Insulin is a temperature-sensitive biologic that requires a strict cold-chain storage environment between 2°C and 8°C.

Loss of Efficacy: If the stolen pens have been stored outside this temperature range, the insulin’s quality and effectiveness may be significantly degraded.
Patient Safety: Using improperly stored injectables poses a direct safety risk to patients who rely on precise dosing for diabetes management.

Guidelines for Patients and Healthcare Providers

The CDSCO and the Directorate General of Health Services have outlined specific steps to prevent these stolen products from reaching consumers:

Group	Recommended Action
Patients	Purchase insulin only from authorized pharmacies and always insist on a proper invoice.
Doctors	Exercise caution when prescribing and monitor patients for any unusual adverse drug reactions.
Pharmacists	Verify batch numbers (specifically 5F0347B) before stocking or dispensing Lantus pens.
Regulators	State drug controllers have been ordered to maintain strict surveillance and may take action under the Drugs and Cosmetics Act, 1940 if stolen stock is found.